Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Institute for Wealth Management LLC.

Institute for Wealth Management LLC. grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 32.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,711 shares of the life sciences company’s stock after purchasing an additional 663 shares during the period. Institute for Wealth Management LLC.’s holdings in Illumina were worth $377,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ILMN. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Illumina during the 3rd quarter valued at about $30,000. State of Wyoming bought a new position in shares of Illumina during the 2nd quarter valued at about $32,000. VisionPoint Advisory Group LLC boosted its position in shares of Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares in the last quarter. Riverview Trust Co boosted its position in shares of Illumina by 203.5% during the 3rd quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Gradient Investments LLC boosted its position in shares of Illumina by 375.0% during the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, CEO Jacob Thaysen acquired 7,330 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research reports. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Stephens reiterated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a report on Wednesday, April 10th. Barclays raised their target price on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Finally, OTR Global reiterated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $167.70.

Illumina Price Performance

NASDAQ ILMN opened at $117.43 on Friday. The company has a 50 day simple moving average of $133.37 and a 200-day simple moving average of $127.89. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $229.58.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.14 earnings per share. Research analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.